Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIB, 28-Day, Randomized, Double-Blind Placebo-Controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Trial Profile

A Phase IIB, 28-Day, Randomized, Double-Blind Placebo-Controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Revefenacin (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Theravance; Theravance Biopharma
  • Most Recent Events

    • 20 May 2015 According to Theravance Biopharma media release, results presented at the American Thoracic Society (ATS) 2015 International Conference.
    • 20 May 2015 Results published in the Theravance Biopharma media release.
    • 10 Mar 2015 In Dec 2014, following the announcement of positive top-line results of the phase IIb program, Theravance Biopharma conducted an end-of-phase II meeting with the FDA to discuss the design of the phase III registrational program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top